#biosig
Text
biographys.
I. [ 𝒮acrilegi̲o̲s̲ ] — 𝒟i𝐚b𝑜𝓁icusㅤׄℳortem𝇃𝇂
❛ㅤp𝑔.‹ 𝐈nfame ’Яojā ›ㅤℳemoria d𝑒١⥐ㅤuna luna
p͟e͟c͟a͟d͟o͟ra (ㅤ @Bvymoon'𝓈ㅤ) ᥱᥒvueᥣta ▭ en llαmαʂ,
PRO—CURÂ 𝆜 𝒮ilenci̲o̲sㅤ▔ 𝘥𝑒 aℊoni͟caㅤ𝑜bse.sióᥒ.
𝐗͟V 𝒮𝘶𝘱𝘭𝘪𝘤𝑎'𝑠 𝐈𝐈. Brūthal. 𝐄p: 𝓘𝐈: 𝟎𝟑 𝙼𝚞𝚗𝚍𝚊𝚗𝑜’𝓈
II. ﹙𝘗𝘳𝘦﹚𝘭𝘶𝘥𝘪𝘰𝘴ㅤ៹ㅤd𝑒⠀𝑺𝘢𝘯𝘨𝘳𝘦ㅤ
⠀
ℳientras⠀⠀DOBLEGÓ⠀ ⠀mí⠀⠀—⠀ 𝓐lma
@/usser ⠀⠀𝓃.⠀E͟𝗇⠀LLENO⠀desasosiego
Confund𝑒⠀ mí⠀ testa⠀﹙ ⠀@/USSER ´𝓼⠀﹚
III. 𝒱𝖾𝗌𝗍𝗂𝗀𝗂𝗈𝗌 ˒ 𝖽𝖾 𝗎𝗇 𝑎𝑚𝗈̂𝗋
苦 ⠀ 𝔰𝖺𝗇—𝗀𝗋𝖾 ͟ ͟ ͟ ˌ ⠀` ⠀ 𝖽𝖾𝗋𝗋𝖺̂𝗆𝖺𝖽𝖺
⠀⠀▍║ ❘❘❘❘❙⠀:⠀ ◖⠀𝐒u ⎯⎯sur͟r͟os ⠀曇 ⠀⌥ ⠀𝑫𝖾𝗌𝖺
‛⠀𝒻𝗂𝖺𝗇𝗍𝖾𝗌⠀ ⑇⠀⠀ 𝕺̀s͟c͟u͟r͟i͟d͟âd ⁹ « @/usser »⠀
⠀⠀
⠀
▎@/usser `𝓈
⠀⠀
IV.
𝓐͟𝗍𝗋𝖺𝗏𝖾samos﹙ ruinas ﹚ 𝒸on pies f𝗂𝗋𝗆𝖾𝗌
y 𝑑𝑒𝑐𝗂𝖽𝗂𝖽𝗈𝗌, 𝖻𝖺𝗃𝗈 ūn c𝑖𝑒𝑙𝑜 𝖾͟𝗇͟𝖿͟𝖾͟𝗋͟𝗆͟𝗈͟ ，
pero con el 𝑎͟𝑙͟𝑚͟𝑎 íntegra. 𝓩etho've.
V. ❲ㅤ༖ ᨈ 𝔩𝗎𝗀𝖺𝗋 ... s𝓵 i𝗇 𝕣uؐؒ֘𝗆͟𝖻͟𝗈͟.ㅤ𝟿𝟽˳
ᙃꮻꮯꮖꮮꭼ，⠀⠀ 𝒅 𝒆 𝒓 𝒏𝒆𝒔𝒔⠀⠀⠀▬▭ ⠀𝄒𝄒 ⠀ 㙜̲‑㘜⠀ ⠀ ᥫ᭡
⠀ 𝓒𝗋𝗒⠀⠀⚟⠀⠀𝒛𝕖𝓁 ⒒⠀⠀ ☶͟ ⠀ 𝗈͟𝗅͟𝖾𝑎𝖽͟𝖺͟𝗌⠀ ⠀ྐ𑣿
ཫ ⠀⠀ ꮋ𝖆𝖘𝐭𝐚 ⠀⠀ ݇ ݈ 𓏧 ⠀⠀⠀ 𝗺͟𝗼⠀͟ ꭱ͟ꮖ͟ꭱ⠀ ⠀ ﹠̲ ⠀𝒏𝑒𝓇
(BONUS)
個 : 𝓔𝓵⠀┉┈ 𝐜𝐨́𝐦𝐨 𝓵ꭺ⠀« 𝗟𝗨𝗡𝗔 » 𝒽𝖾𝗋𝗆𝗈𝗌𝖺
𝑓𝑟𝑖̨𝑎'ℯ 🃌 #i͟n͟a͟l͟c͟a͟n͟𔕴z͟a͟b͟l͟e͟ 𝑄𝗎𝖾 𝚎𝚗 𝗌u
℘𝖺𝗌𝗂͡𝗈𝗇 𝗆𝖾 。 𝗉𝖾𝗋͟͟͟𝖽𝗂̀𝗈.
#twitter bios#bios dark#short bios#biosig#kpop bios#bios jungkook#soft bios#bioinspired#bios#biography
2K notes
·
View notes
Text
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
New Post has been published on https://medianwire.com/why-cyclerion-therapeutics-shares-traded-lower-by-around-38-here-are-70-biggest-movers-from-yesterday/
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers
Green Giant Inc. (NASDAQ:GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.
Atlis Motor Vehicles, Inc. (NASDAQ:AMV) climbed 95.5% to close at $24.49.
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) gained 83% to settle at $7.98.
Pineapple Energy Inc. (NASDAQ:PEGY) shares climbed 64.9% to close at $4.55 after jumping 93% on Wednesday. Pineapple Energy recently named Eric Ingvaldson as new Chief Financial Officer.
WM Technology, Inc. (NASDAQ:MAPS) rose 64.3% to close at $2.76.
Statera Biopharma, Inc. (NASDAQ:STAB) gained 62.8% to close at $0.2283 on Thursday. Statera Biopharma was recently granted European patent number EP3206708 titled “Methods And Compositions For The Treatment Of Radiation-Related Disorders.”
Code Chain New Continent Limited (NASDAQ:CCNC) shares gained 46.6% to close at $0.2465.
SpringBig Holdings, Inc. (NASDAQ:SBIG) jumped 44.2% to close at $1.19.
Kiromic BioPharma, Inc. (NASDAQ:KRBP) gained 44.3% to close at $0.3923 after the company announced it received feedback from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel development strategy.
Clever Leaves Holdings Inc. (NASDAQ:CLVR) jumped 36.7% to settle at $0.8198.
Motus GI Holdings, Inc. (NASDAQ:MOTS) rose 38.3% to close at $2.60 after the company was granted a Us patent titled ‘Cleaning Method for Prepless Colonoscopy.’
Guardion Health Sciences, Inc. (NASDAQ:GHSI) jumped 31% to close at $0.1808 as the company announced clinical results indicating viactiv omega boost gel bites showed increase in Omega-3 levels in 4 weeks.
Tilray Brands, Inc. (NASDAQ:TLRY) gained 30.9% to settle at $3.90. Shares of cannabis companies traded higher after President Biden issued a statement on marijuana reform, which mentioned pardoning ‘all prior federal offenses of simple marijuana possession.’
SAI.TECH Global Corporation (NASDAQ:SAI) rose 30.4% to settle at $4.89.
BioSig Technologies, Inc. (NASDAQ:BSGM) jumped 28.8% to settle at $0.88.
Addentax Group Corp. (NASDAQ:ATXG) gained 28.4% to close at $3.44.
COMSovereign Holding Corp. (NASDAQ:COMS) rose 26.9% to settle at $0.0773.
HeartBeam, Inc. (NASDAQ:BEAT) shares climbed 26.5% to close at $5.73 after the company announced it expanded its product portfolio pipeline to include smartwatch connectivity.
DAVIDsTEA Inc. (NASDAQ:DTEA) climbed 26% to close at $0.8948.
WeTrade Group, Inc. (NASDAQ:WETG) rose 25.8% to close at $1.16.
Provention Bio, Inc. (NASDAQ:PRVB) surged 25.7% to close at $6.22 after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch of its lead investigational drug candidate teplizumab.
The Valens Company Inc. (NASDAQ:VLNS) rose 25.1% to settle at $0.8871.
ToughBuilt Industries, Inc. (NASDAQ:TBLT) gained 25% to close at $2.90. The company recently announced new distributor agreements in Germany.
Richardson Electronics, Ltd. (NASDAQ:RELL) gained 24.6% to close at $19.12 following upbeat Q1 results.
BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 23.6% to close at $2.72.
Senti Biosciences, Inc. (NASDAQ:SNTI) gained 23.5% to close at $6.52.
SNDL Inc. (NASDAQ:SNDL) rose 23.5% to close at $2.79. Shares of cannabis companies traded higher after President Biden issued a statement on marijuana reform, which mentioned pardoning ‘all prior federal offenses of simple marijuana possession.’
Kintara Therapeutics, Inc. (NASDAQ:KTRA) climbed 23.5% to close at $0.1274.
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) rose 23.4% to settle at $0.2098.
Canopy Growth Corporation (NASDAQ:CGC) jumped 22.2% to close at $3.75. Shares of cannabis companies traded higher after President Biden issued a statement on marijuana reform, which mentioned pardoning ‘all prior federal offenses of simple marijuana possession.’
Rain Therapeutics Inc. (NASDAQ:RAIN) gained 19.5% to close at $4.71.
Agenus Inc. (NASDAQ:AGEN) climbed 18.1% to close at $2.80.
Compass, Inc. (NYSE:COMP) jumped 16.1% to close at $2.96.
Innovid Corp. (NYSE:CTV) gained 15.7% to close at $2.72.
PureTech Health plc (NASDAQ:PRTC) rose 14.9% to close at $31.01.
Plus Therapeutics, Inc. (NASDAQ:PSTV) gained 14.7% to close at $0.5450. Plus Therapeutics recently reported it finalized and signed a grant contract with the Cancer Prevention & Research Institute of Texas for its previously announced $17.6 million Product Development Research funding award.
Revelation Biosciences, Inc. (NASDAQ:REVB) gained 14.4% to close at $0.2901 after the company announced an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide, for treating or preventing infections.
Zovio Inc (NASDAQ:ZVO) rose 14% to close at $0.1670 after declining around 7% on Wednesday.
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) rose 13.7% to close at $1.33.
Cronos Group Inc. (NASDAQ:CRON) jumped 13.5% to close at $3.36. Shares of cannabis companies traded higher after President Biden issued a statement on marijuana reform, which mentioned pardoning ‘all prior federal offenses of simple marijuana possession.’
BZ Wire
Perion Network Ltd. (NASDAQ:PERI) gained 13% to close at $23.01. Perion issued preliminary Q3 results. The company said it sees Q3 revenue of $158 million.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) rose 12.7% to close at $6.46.
Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) gained 11.5% to close at $2.90. Lixiang Education Holding recently posted 1H loss of $0.01 per share.
TOP Financial Group Limited (NASDAQ:TOP) rose 10.2% to close at $17.90.
WISeKey International Holding AG (NASDAQ:WKEY) rose 6.6% to close at $1.79 after the company reported 9-Month preliminary results, The company reported revenue of $20.5 million, a 69% increase from the year-ago period.
Pinterest, Inc. (NYSE:PINS) rose 4.9% to close at $25.83. Goldman Sachs upgraded Pinterest from Neutral to Buy and raised the price target from $24 to $31.
Don’t forget to check out our premarket coverage here .
Losers
Jowell Global Ltd. (NASDAQ:JWEL) shares fell 45.4% to close at $1.53. Jowell Global recently posted 1H loss of $0.30 per share.
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) fell 37.6% to close at $ 0.5870 after the company announced a mitochondrial disease-focused strategy. The plan will include a 45% workforce reduction.
Top Ships Inc. (NASDAQ:TOPS) fell 35.2% to close at $6.40 after jumping 82% on Wednesday. TOP Ships recently announced 1H FY22 revenue of $38.8 million.
Applied Therapeutics, Inc. (NASDAQ:APLT) dropped 33.5% to close at $0.6320 after the company disclosed data trend in AT-007 ACTION-galactosemia kids pediatric trial. The company said ‘The study did not yet reach statistical significance at 12 months of treatment.’
Chardan NexTech Acquisition 2 Corp. (NASDAQ:CNTQ) fell 30.4% to close at $15.24 after jumping around 103% on Wednesday.
Nutex Health Inc. (NASDAQ:NUTX) fell 26.3% to close at $0.8998.
American Rebel Holdings, Inc. (NASDAQ:AREB) shares fell 26% to close at $0.37 after jumping 16% on Wednesday.
Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 25.8% to close at $0.2462 after jumping 72% on Wednesday.
Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 25.7% to close at $6.29. Avenue Therapeutics priced its 3.6 million unit offering at $3.30 per unit.
AngioDynamics, Inc. (NASDAQ:ANGO) dropped 19.5% to close at $17.34 after the company reported worse-than-expected Q1 results.
Super League Gaming, Inc. (NASDAQ:SLGG) dropped 19.2% to close at $0.7512.
FingerMotion, Inc. (NASDAQ:FNGR) fell 19% to close at $7.18 after jumping 29% on Wednesday.
FOXO Technologies Inc. (NYSE:FOXO) fell 18% to close at $1.32.
Gold Royalty Corp. (NYSE:GROY) dropped 16.6% to close at $2.37.
Integer Holdings Corporation (NYSE:ITGR) fell 16.6% to close at $55.28. Integer sees preliminary Q3 revenue of $342 million to $344 million and adjusted EPS of $0.86-$0.99.
United Time Technology Co., Ltd. (NASDAQ:UTME) dropped 16% to $1.68.
Esports Entertainment Group, Inc. (NASDAQ:GMBL) fell 14.3% to close at $0.1384. HC Wainwright & Co. downgraded Esports Entertainment from Buy to Neutral and lowered the price target from $1.5 to $0.15.
Li Auto Inc. (NASDAQ:LI) dropped 12.3% to close at $20.95.
Spark Networks SE (NASDAQ:LOV) dipped 11.4% to close at $2.17.
5E Advanced Materials Inc. (NASDAQ:FEAM) fell 11.4% to close at $11.70. Baird maintained an Outperform rating on the stock and lowered its price target from $36 to $21.
Resources Connection, Inc. (NASDAQ:RGP) fell 9.9% to close at $16.18 following Q1 results.
Altice USA, Inc. (NYSE:ATUS) dropped 8.9% to close at $5.75.
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) dropped 8.8% to close at $1.56.
Waste Connections, Inc. (NYSE:WCN) dropped 65% to close at $134.72.
Read the full article here
0 notes
Text
Oncology Nutrition Market Research, Segmentation, Key Players Analysis & Forecast By 2032
Amid the COVID-19 crisis, the global market for Oncology Nutrition estimated at US$1.1 Billion in the year 2021, is projected to reach a revised size of US$3.14 Billion by 2027, growing at a CAGR of 8.9% over the analysis period.
Malnutrition triggered by cancer treatment is the most common side-effect among cancer patients. Specifically, malnutrition is more prevalent among individuals with digestive cancers or head and neck cancers.
Head & Neck Cancer, one of the segments analyzed in the report, is projected to grow at a 7.8% CAGR to reach US$472.2 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Stomach & Gastrointestinal segment is readjusted to a revised 10.9% CAGR for the next 7-year period. This segment currently accounts for a 22.9% share of the global Oncology Nutrition market.
Continuously increasing number of cancer patients is posing serious healthcare challenges for various countries. Several healthcare professionals consider inappropriate diet as well as inactive lifestyle for approximately 85% of global cancer cases. On the other hand, obesity and food attributes for 35% as well as 30% of all cancer related deaths, respectively.
Consuming large quantities of nutritious food significantly improve stamina and strength of patients undergoing cancer treatment. Owing to their abilities to prevent growth of cancer cells, demand for nutritional food is witnessing an upward momentum. Propelled by rising popularity of homecare nutritional products, the global market for oncology nutrition is exhibiting robust growth.
In order to tap the available opportunity, companies are devising a broad range of innovative strategies. Hospitals, retail pharmacies, and online pharmacies are some of the major end-users of oncology nutrition segment. Hospitals currently account for majority of share in the global oncology nutrition market, due to constantly increasing number of cancer patients. In order to ensure timely treatment, various leading global healthcare providers are now constructing high-end cancer diagnosis and care centers.
The U.S. Market is Estimated at $412.6 Million in 2021, While China is Forecast to Reach $165 Million by 2026
The Oncology Nutrition market in the U.S. is estimated at US$412.6 Million in the year 2021. The country currently accounts for a 35.62% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$165 Million by the year 2026 trailing a CAGR of 10.6% through the analysis period.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR while Rest of European market (as defined in the study) will reach US$182.4 Million by the close of the analysis period.
The entire market for oncology nutrition negates a highly important cancer nutrition element, which is the patient`s daily dietary regimen. Even though nutritional formulas and nutraceuticals are great items for selling with their respective beneficial impacts on a patient`s nutritional status, only a handful of such producers and marketers are actually interested in educating patients on a healthy diet`s importance in the long-run. Nevertheless, suppliers are already providing those items needed for short-term gain and patients too, prefer quick fixes.
Key Players
FMC Corporation
Danone India
Abbott
Aceto
B. Braun Melsungen AG
Baxter
Fresenius Kabi AG
Global Health Products, Inc.
Hormel Foods Corporation
Mead Johnson & Company, LLC
Meiji Holdings Co., Ltd
Nestlé S.A.
BioSig Technologies, Inc.
Auris Health, Inc.
KEY SEGMENTS
By Cancer Type
Head & Neck Cancer
Stomach & Gastrointestinal Cancers
Blood Cancer
Breast Cancer
Lung Cancer
Other cancers
By End Use:
Hospitals
Home Care
Others
By Geography:
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe (RoE)
Asia Pacific
Latin America
Middle East and Africa
For more Information @ https://www.futuremarketinsights.com/reports/oncology-nutrition-market
0 notes
Text
3D Cardiac Mapping Market Trends, Key Players, And Forecast 2027
Market Overview:
3D Cardiac Mapping Market will grow at a CAGR of 10.8%. According to VPR analysis, the market value will reach up to USD 4.1 billion during the forecast 2027
The 3D Cardiac Mapping Market is expected to develop with a critical CAGR attributable to the increment in number of patients with arrhythmia and other cardiovascular problems, rising strain to lessen finding mistakes and expanding medical services consumption. The central point driving the development of 3D Cardiac Mapping Markets is the accuracy and patient security empowered by continuous observing. The increment in maturing populace who are more inclined to ongoing heart problems will lift the interest for the 3D Cardiac Mapping Market. The increment in pervasiveness and finding pace of cardiovascular sickness is the central point which is provoking the interest for 3D Cardiac Mapping Markets. The 3D heart planning additionally helps in diminishing the hour of finding. The controlling variables for the 3D Cardiac Mapping Market are significant expense of administrations and restricted reception pace of the frameworks.
Cardiovascular planning is a procedure where the data from heart electro grams is assembled and shown. Cardiovascular planning is utilized to analyze the heart rhythms particularly if there should be an occurrence of arrhythmia. The cardiovascular planning strategy is typically finished by embedding catheter into the heart chamber percutaneously and recording the electro grams successively, this is done to associate the electro grams with cardiovascular life structures. The new 3D Cardiac Mapping Market make the three-layered model of any office of heart and can follow accurate area of the catheter. This permits development of the catheters without utilizing X-beam. They are intended to work on the goal and gain brief heart actuation maps.
Market Key Players:
Medtronic (Ireland), Micro Port Scientific Corporation (China), Solutions SA (Switzerland), Acutus Medical (US), Koninklijke Philips N.V. (Royal Philips) (Netherlands), Lepus Medical (China), BIOTRONIK (Germany), AngioDynamics (US), BioSig Technologies (US), Catheter Precision (US), Epmap-System (Germany)
Get More Professional and Technical Industry Insights @ https://valuepropresearch.com/report/3d-cardiac-mapping-market-109/
Market Development:
A portion of the new improvements are molding the state of the worldwide 3D Cardiac Mapping Market Researchers have adopted a weighty strategy which empowers them to make a nearest formed counterfeit heart. They acquainted 3D bio-printing innovation with make a heart-like shape and structure, and furthermore gathered cells of greasy tissue from patients. Researchers reinvented the greasy tissue cells to transform into pluripotent undifferentiated organisms and adjusted non-cell materials to shape "bioink".
Specialists blended both undifferentiated organisms and bioink to begin cell separation process which wound up framing heart cells. It is interestingly that a heart with veins and cells is made utilizing 3D printing innovation. Right now, researchers are zeroing in on fostering the printed heart further stressing on heart's constrictions or siphoning systems.
0 notes
Note
4, 10, 11 and 17?
answered 17!
OUGH OK this from alien au pt 1:
Luther sighed in relief and tapped his implant, summoning up the transfer papers and shooting them off towards the captain’s databank. The captain called them up in front of him, projecting them as a holographic image from his right eye. It was an archaic function, one Luther thought most implants had already phased out, and he watched in fascination as the captain painstakingly read over every detail, then signed the hologram with his finger - an actual signature! Rather than a biosig! - and dismissed it again. He saw Luther staring and grinned sheepishly. “Can’t get the hang of it in my own head,” he said. “Always thought better out loud, myself. Anyway, welcome to the crew, Officer Algers."
im really proud of this because i think it establishes two things fairly effectively - that this is set so far in the future that technology that seems super advanced to us is archaic by their standards, and that cam is old school and maybe not great with tech and could use a certain tech savvy cutie to help him out. i love when stories set in a different time or place don't explain every detail to you but incoporate their quirks and differences in a way that feels natural and so you pick up on them through context clues, and i really liked coming up with the neural implant databank thingies. plus i like cam calling it 'thinking out loud' to project an image from his head. as someone who talks to himself out loud frequently because i lose my train of thought super easily, i feel like this is exactly what i would do with this kind of technology.
1. get an idea
2. try to draw the idea
3. drawing dont work
4. in several frenzied bursts with little to no proofreading, slap as much as i can into a word doc like so much clay upon a pottery wheel
5. anxiously send wip to friends for validation and head pats
6. run out of steam, cough out a few more stray sentences, say fuck it, post.
Y'ALL WRITE SO MUCH. like as in you find a way to DESCRIBE things so fully and completely and it puts the perfect mental image into my head. and then in my work im like 'there are literally no more words in the english language i think i used all of them up [has written 800 words]'. meanwhile yall r painting fucking. full vistas with yr words. my god.
9 notes
·
View notes
Text
Week 1 - I’m a grad student!
This week was one of the hardest I’ve ever experienced. The learning curve to being a full-time working parent and grad student is STEEP. All the planning in the world couldn’t have prepared me for this. A few reflections (and wins!) from this week:
Reading textbooks and academic research is WAY different than my current guilty pleasure - Diana Gabaldon’s “Go Tell the Bees That I Am Gone”. My eyes can’t seem to keep the words straight and jump around the electronic page. I long for a physical textbook (it’s on back order). That said, I do love the searchability (but I am an old and can also use an index :-)).
I completely over thought my first discussion post and assignment, but I got them in earlier than the deadlines. AND I did get a 100 on my first quiz! Now I anxiously await the discussion and assignment grades
Community is EVERYTHING! Just like my Women in Testing community, this cohort is amazingly welcoming and helpful as we learn together. We quickly found smaller study groups to share tips and check our thinking and help each other through the week
Office hours are important. Ignore the “optional”. I can’t make it to both for personal/family reasons, but my community has my back (and I have theirs). We share notes and talk about important things, like HOW TO READ A RESEARCH ARTICLE (start to finish? Oh no. Abstract first. Then conclusions. Then the stuff in the middle).
I’m also now not the same reader as I was in my youth. I need assistive technology. Bigger font. Better contrast. Read aloud options. Reading online triggered three migraines. Ugh. Keyboard navigation. As someone that’s been in Ed tech for 17 years some of the solutions I used this week PAIN me after having tested for accessibility.
BioSig? Lockdown browser? Security theater I say. I’m too old and worked too hard to even be tempted to cheat for what I want out of this degree. I’m actually offended it’s a thing. (Psst. It’s also ableist).
But enough about my experiences. What did we go over? This week was an intro to I-O psych
What exactly IS industrial and organizational psychology? A form of applied psychology, I-O psychology is the science of human behavior as it pertains to work. Industrial psychology aspects cover topics such as employee selection, performance management, procedures and processes, etc. Organizational psychology tends to look at areas like leadership, teamwork, and more. It’s rare to study one over the other, given the impact each has on “the other side”. My preference though right now is organizational ;-)
It was fascinating to see the impact of I-o psych throughout historical events. From selection methods in the army in World War I through more classification methods in World War II, an impact on civil rights and Americans with Disabilities acts. I’d never thought of it from that perspective before. And if you’ve never heard of Lillian Gilbreth go look her up. Too tired to write more about her right now :-)
One area that gives me pause, and I kind of dread the course, is employee selection methods. If science tells us that selection tests work, wtf happened to me? On paper I did not make sense. I had to take the Computer Programmer Aptitude and Battery test to get my job. I am pretty sure someone told me I did awful (omg I hate tests!). We have also since done away with that required part of the interview process. How do we ensure we consider the context of the individual? How do we check our biases and explore what biases may be introduced in these tests? Well, at least I have a few questions to go after when it’s time.
Another interesting thing we discussed was the scientist-practitioner gap. It’s almost like this field needs its own form of DevRel to make sure the science is making its way to the practitioners.
Anyway, a hard, but good week teeing up topics for the future - glad to see I’m at least still interested in (even if skeptical… hello performance management! It’s totally review season here and I still haven’t written mine up).
That’s all for now. Week 2 will be interesting as I’m slammed in work and life, but I have a tiny bit more confidence having made it through week 1. 1 down, 79-ish to go!).
Thanks to everyone that has reached out and supported me so far - especially on the days I wanted to quit (yes, already at least three of those). But especially to my husband, best friend and partner, Scott, who has been a tremendous help and encouraged me to stick with it as I cried myself to sleep on more than one occasion.
5 notes
·
View notes
Text
BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018
BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018
BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018 – World News Report – EIN News <meta name="generato... Nasdaq Search Results
View On WordPress
0 notes
Text
BioSig se presentará en Heart Rhythm 2022
BioSig se presentará en Heart Rhythm 2022
Westport, CT, 19 de abril de 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” o la “Compañía”), una compañía de tecnología médica que avanza en el flujo de trabajo de electrofisiología al ofrecer una mayor fidelidad de la señal intracardíaca a través de su plataforma de procesamiento de señales, anunció hoy que la Compañía participará en Heart Rhythm 2022, que tendrá…
View On WordPress
0 notes
Text
BIOS
鑏ㅤ ㅤㅤꓣׅ፝𝖨𝖳𝖴ۨۨꜲ᳟𝆬𝖫ㅤ ㅤㅤ♰ 𝗗ۨۨꓱ꯭𝗩𝗜࣮𝖫ㅤㅤㅤﷴۣ ㅤ ㅤ𝆬ㅤ ㅤ𓃹
ꔫㅤㅤׄㅤㅤノㅤㅤ𝗄꯭ɩ𝗍꯭𝗍ɥㅤㅤㅤㅤ ㅤㅤ𝗅𝗈𝗏ᧉㅤㅤ⊹ㅤㅤ♡⃝ㅤ
ㅤ خج ³² 𒌀 ！ ▎ .. # in 𝐡𝑒𝖑𝖑
𝐒︭e︭e︭k︭ ┃ 𝐃𝗲𝘀𝘁𝗿oy - ⍛ 𝗦𝗡𝗨𝗙ꟻ
،،⠀ ⠀ : 𝓜𝖾𝗇𝗍𝖺𝗅 “ & . . . '𝘱𝗎𝗇𝗂𝗌𝗁 — 𝗆𝘦𝗇𝗍.
𩊠ㅤㅤ𝐓𝗋𝖺𝗂𝖼𝗂𝗈𝗇𝖾𝗋𝗈ㅤㅤᚲㅤㅤ𝑑𝑣. ㅤㅤ𔕭ㅤㅤ𝒜rtㅤㅤ
ㅤ ㅤ ܮܠܛܔ ㅤ ༒ㅤ ㅤ ㅤ꙰᪶𑁄ㅤㅤㅤ 𐍬𝅮᷃ㅤㅤㅤ
▌ 𝒊. 𝖬𝖯𝖮𝗟𝖴𝖳𝖮𝖲 ܢܔܠ ㅤ ㅤㅤ
962 notes
·
View notes
Text
Cardiac Mapping Market Development, Key Opportunities and Analysis of Key Players to 2027
Cardiac Mapping Market Overview:
Maximize Market Research provides a quick overview of Cardiac Mapping market, including the most up-to-date market data and the most thorough examination of its characteristics. The evaluation provides a broad overview of the market, includes common topics, and designer information based on the scenario. This examination will assist you in determining how to approach the market and obtaining information about the current state of the area. This research method was used to investigate the global Cardiac Mapping market, and the findings of these investigations are fairly presented in this report.
Market Scope:
The Cardiac Mapping Market report provides a detailed analysis of major companies by market, industry, and geographic district to assist you in identifying your neighbourhoods and the general competition. The study also includes a thorough examination of the critical environment and key items offered by the firms, as well as venture incredible doors open to wealthy supporters in the small industry.
Cardiac Mapping The study includes an in-depth examination as well as material on trends, components, and other topics. The main trends that will effect business tasks are identified. It aids in identifying the truths included in the study, which puts out the severe scene of major corporations, market factors, and many opinions that may support you in determining whether your current marketing strategy is effective. If you're on the right path, and how can you make it better?
Request for free sample:
https://www.maximizemarketresearch.com/request-sample/116413
PESTEL Analysis:
Maximize Market Research's reports include a PESTEL Analysis to help you design your exchange operations. Political issues such as spending policy, environmental regulations, taxation, and so on help you in determining the extent to which authority can influence the market Cardiac Mapping . Loan fees, conversion scale, development and payment rates, least salaries, and other financial elements aid in reducing the causes of financial action.
Get more Report Details:
https://www.maximizemarketresearch.com/market-report/global-cardiac-mapping-market/116413/
Key Players:
• EP Solutions SA (Switzerland)
• Acutus Medical (US)
• Koninklijke Philips N.V. (Royal Philips) (Netherlands)
• Lepu Medical (China)
• BIOTRONIK (Germany)
• AngioDynamics (US)
• BioSig Technologies (US)
• APN Health (US)
• CoreMap (US)
• Kardium (Canada)
• Catheter Precision (US)
• Epmap-System (Germany)
Regional Analysis:
Our informative Regional metrics enable you to get completely knowledgeable about the Cardiac Mapping commercial area on a local level. Any large evaluation of feasible inclusion possibilities in reaction to the development of the Global commercial hub requires a flawless understanding of local energy, economic, legal, and topographical elements. Our assessments will enable you to comprehend nearby pieces of information, ensuring Cardiac Mapping # commercial centre outcomes and neighbourhood blast chances despite national imperatives.
Key Questions answered in the Cardiac Mapping Market Report are:
In the Cardiac Mapping market, which item segment holds the largest share of the pie?
What is the current state of the market Cardiac Mapping in terms of competition?
What are the main factors influencing the Cardiac Mapping market's growth?
In the Cardiac Mapping market, where is the most severe fraction of the whole industry?
What is the CAGR of the Cardiac Mapping market during the forecast period?
Which potential application has established itself as the dominant segment in the Cardiac Mapping market?
Who are the Cardiac Mapping market's most important players?
What are the major trends that are likely to emerge in the Cardiac Mapping market in the near future?
In 2027, how big will the Cardiac Mapping market be?
Which group has the largest slice of the pie Cardiac Mapping ?
0 notes
Photo
❤️🧡💛 The Sirens of Mars: Searching for Life on Another World: We wish it was longer! https://t.co/rdW3oVqXXV @biosigs @CrownPublishing Reviewed by @billcap11 https://t.co/ScLaEuh1sK #SFF (from the archive)
0 notes
Text
Oncology Nutrition Market: Creating Opportunity, Demands & Supply, Value Chain & Process- upto 2032
Amid the COVID-19 crisis, the global market for Oncology Nutrition estimated at US$1.1 Billion in the year 2021, is projected to reach a revised size of US$3.14 Billion by 2027, growing at a CAGR of 8.9% over the analysis period.
Malnutrition triggered by cancer treatment is the most common side-effect among cancer patients. Specifically, malnutrition is more prevalent among individuals with digestive cancers or head and neck cancers.
Head & Neck Cancer, one of the segments analyzed in the report, is projected to grow at a 7.8% CAGR to reach US$472.2 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Stomach & Gastrointestinal segment is readjusted to a revised 10.9% CAGR for the next 7-year period. This segment currently accounts for a 22.9% share of the global Oncology Nutrition market.
Continuously increasing number of cancer patients is posing serious healthcare challenges for various countries. Several healthcare professionals consider inappropriate diet as well as inactive lifestyle for approximately 85% of global cancer cases. On the other hand, obesity and food attributes for 35% as well as 30% of all cancer related deaths, respectively.
Consuming large quantities of nutritious food significantly improve stamina and strength of patients undergoing cancer treatment. Owing to their abilities to prevent growth of cancer cells, demand for nutritional food is witnessing an upward momentum. Propelled by rising popularity of homecare nutritional products, the global market for oncology nutrition is exhibiting robust growth.
In order to tap the available opportunity, companies are devising a broad range of innovative strategies. Hospitals, retail pharmacies, and online pharmacies are some of the major end-users of oncology nutrition segment. Hospitals currently account for majority of share in the global oncology nutrition market, due to constantly increasing number of cancer patients. In order to ensure timely treatment, various leading global healthcare providers are now constructing high-end cancer diagnosis and care centers.
The U.S. Market is Estimated at $412.6 Million in 2021, While China is Forecast to Reach $165 Million by 2026
The Oncology Nutrition market in the U.S. is estimated at US$412.6 Million in the year 2021. The country currently accounts for a 35.62% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$165 Million by the year 2026 trailing a CAGR of 10.6% through the analysis period.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR while Rest of European market (as defined in the study) will reach US$182.4 Million by the close of the analysis period.
The entire market for oncology nutrition negates a highly important cancer nutrition element, which is the patient`s daily dietary regimen. Even though nutritional formulas and nutraceuticals are great items for selling with their respective beneficial impacts on a patient`s nutritional status, only a handful of such producers and marketers are actually interested in educating patients on a healthy diet`s importance in the long-run. Nevertheless, suppliers are already providing those items needed for short-term gain and patients too, prefer quick fixes.
Key Players
FMC Corporation
Danone India
Abbott
Aceto
B. Braun Melsungen AG
Baxter
Fresenius Kabi AG
Global Health Products, Inc.
Hormel Foods Corporation
Mead Johnson & Company, LLC
Meiji Holdings Co., Ltd
Nestlé S.A.
BioSig Technologies, Inc.
Auris Health, Inc.
KEY SEGMENTS
By Cancer Type
Head & Neck Cancer
Stomach & Gastrointestinal Cancers
Blood Cancer
Breast Cancer
Lung Cancer
Other cancers
By End Use:
Hospitals
Home Care
Others
By Geography:
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe (RoE)
Asia Pacific
Latin America
Middle East and Africa
For more Information @ https://www.futuremarketinsights.com/reports/oncology-nutrition-market
0 notes
Text
Is the Federal Circuit too Trigger-Happy Invalidating Means Claims?
by Dennis Crouch
Rain Computing has filed an interesting petition to the Supreme Court focusing on indefiniteness and means-plus-function claims. Rain Computing, Inc. v. Samsung Electronics America, Inc., No. 21-170 (Supreme Court 2021). Rain’s asserted claims require a “user identification module configured to control access of … software application packages.” The Federal Circuit interpreted “module” as a non-structural nonce word. As such, the court interpreted the module element a means-plus-function limitation under 35 U.S.C. § 112(f). The problem though was that the specification did not disclose any corresponding structure “clearly linked” with the claimed function. As such, the Federal Circuit found the claims invalid as indefinite.
The first question in the petition focuses on the courts trigger-happy approach to invalidating means claims and the interpretive difference between a claim limitation and the claim as a whole. Although courts often construe individual claim limitations, indefiniteness is generally determined by considering the claim as a whole in light of the specification and the prosecution history and asking whether the claim informs “with reasonable certainty those skilled in the art about the scope of the claim.” Nautilus. The idea here is that the Federal Circuit should have asked the broader question — would someone of skill in the art have reasonable certainty as to the claim scope? Instead, the court did a shortcut and effectively held that the element-by-element corresponding-structure is a requirement of patentability if means language is used. The petitions also notes the construction provision of 112(f) requiring that “such claim shall be construed to cover the corresponding structure …” On its face, the provision focuses on construction of the whole claim, not just the means-element.
The second question is directed toward the Federal Circuit’s conclusion that the specification disclosed only a ‘general purpose computer’ when the district court held otherwise. The petition suggests that change-of-course would require clear-and-convincing evidence before the claim can be invalidated. The underlying assumption of this argument is that some aspect of interpreting the specification is a question of fact (rather than a question of law).
Whether a patent claim may be invalidated for indefiniteness only if, under 35 U.S.C. § 112, para. 2 (now subsection 112(b)) as construed by Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898, 901 (2014), the whole claim, “read in light of the specification delineating the patent, and the prosecution history, fail[s] to inform, with reasonable certainty those skilled in the art about the scope of the claim” and 35 U.S.C. § 112(f) (previously 112 para. 6) affects only coverage of a combination claim of which an element is expressed as allowed by the subsection?
Whether the United States Court of Appeals for the Federal Circuit panel in this case erred by invalidating a patent as indefinite without mentioning 35 U.S.C. § 112, para. 2 (now subsection 112(b)) and applying the Nautilus test and by substituting, without clear and convincing evidence, its conclusion of a “general purpose computer” for the district court’s finding of no “general computer”?
[Petition for Writ of Certiorari]
= = = =
I’ll note here that Rain Computing is represented by the Hsuanyeh Law Group, founded by Hsuanyeh Chang. Dr. Chang is also the listed inventor of the patent here and is CEO of the petitioner Rain Computing.
Is the Federal Circuit too Trigger-Happy Invalidating Means Claims? published first on https://immigrationlawyerto.tumblr.com/
0 notes
Last Seen Blogs
astrology-realm
Astrology Realm
rockinhand
ride horsie with me
orchid-20
Alli W.
markches
Awesome Fellas Studios x Mark Ches